Heron Therapeutics | HRTX - Gross Profit On Sales


Heron Therapeutics reported $29.47M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
ALKERMES USD 375.31M 43.98M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amarin USD 23.17M 961K Dec/2025
ANI Pharmaceuticals USD 143.88M 19.7M Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 75.25M 1.52M Jun/2026
Eisai JPY 183.24B 29.83B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 356.19M 99.73M Jun/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 133.91M 7.27M Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Veracyte USD 108.55M 7.39M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026